EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
The EAHP EU Monitor is a regular round up of news relevant to hospital pharmacy in Europe.
You can subscribe to receive the EAHP EU Monitor by email HERE.
Disasters such as storms, earthquakes and wildfires are happening more and more frequently. To better prepare hospital pharmacists – who are one of the fundamental cornerstones for effective and efficient performance of rescue operations before and during a catastrophe – the European Association of Hospital Pharmacists (EAHP) has made available a European List of Emergency Medicines (ELEM).
The ELEM was developed after an evaluation of the most common causes of natural disasters in Europe, their consequences and the role of the hospital pharmacy before and during the catastrophe. The report, prepared by Dr D. Leonardi Vinci, Dr E. Di Martino, Dr R. Giammona, Dr M. E. Faggiano and EAHP Board members Dr P. Horák, Dr N. Miljković, Dr D. Makridaki and Dr P. Polidori, outlines how the ELEM was created including the criteria used and the considerations made which are specific for Europe, such as the reliable availability of different medicines.
Two support tools for clinicians, pharmacists and institutions have been made available, the disaster medicine assessment template and the disaster stock management template. The disaster medicine assessment template is based on the most relevant World Health Organisation emergency list and was adapted to the European scenario. It also includes a calculation sheet that quantifies the number of drugs needed and a self-assessment indicator that allows each hospital to rapidly evaluate its percentage of compliance with the proposed ELEM. The disaster stock management template enables the management of drug stocks during an emergency, automatically updates the quantity of stock available and keeps notes regarding all restock and withdrawal movements through a printable form.
Learn more about the European List of Emergency Medicines HERE
The survey aims at collecting information on opioid stewardship practices across the world. Questions touch on policies and regulations, logistics, clinical practices and the perceptions/attitudes toward opioid stewardship. It will take about 20 to 30 minutes to answer the survey.
Access the survey HERE
In early March, the European Medicines Agency shared information on the start of an assessment of medicines for which studies have been conducted by Panexcell Clinical Laboratories Priv. Ltd, a review of the cancer medicine Yondelis and an update on nitrosamines in EU medicines.
Start of review of medicines for which studies have been conducted by Panexcell Clinical Laboratories Priv. Ltd at its site in Mumbai, India
EMA has started a review of medicines for which studies have been conducted by Panexcell Clinical Laboratories Priv. Ltd at its site in Mumbai, India. This follows a good clinical practice inspection which raised concerns about the study data used to support marketing authorisation applications of some medicines in the EU. The inspection was carried out jointly by Austrian and German authorities in October 2019 in the context of the evaluation of an application for marketing authorisation of a medicine.
Having considered the inspection findings, the German medicines agency requested EMA to assess the impact of these findings on the benefits and risks of medicines that have been authorised in the EU based on studies performed by Panexcell Clinical Laboratories Priv. Ltd at its site in Mumbai. EMA has also been requested to look at the impact of the findings on medicines currently being evaluated for authorisation. EMA will now review the available data to determine if any action is necessary to protect public health.
More information is available HERE
CHMP has started a review of the cancer medicine Yondelis (trabectedin) used to treat ovarian cancer
EMA’s Committee for Medicinal Products for Human Use (CHMP) has started a review of the cancer medicine Yondelis (trabectedin), used to treat ovarian cancer (cancer of the ovaries) and soft-tissue sarcoma (a type of cancer that develops from the soft, supporting tissues of the body). The review started after a clinical study (OVC-3006) investigating the use of Yondelis in patients with ovarian cancer was stopped ahead of time, because an interim analysis of the results showed that, overall, patients treated with Yondelis plus pegylated liposomal doxorubicin (PLD, another cancer medicine) did not live longer than patients given PLD alone.
Although there were some differences in the types of patients enrolled in study OVC-3006 compared with those of the study on which the authorisation of Yondelis for ovarian cancer was based, study OVC-3006 also included patients for whom Yondelis would be indicated. EMA will, therefore, review the available data to assess whether the results from study OVC-3006 have an impact on the authorised use of Yondelis in patients with ovarian cancer. This review does not cover the use of Yondelis for the treatment of soft-tissue sarcoma. While the review is ongoing, Yondelis can continue to be used for the treatment of both ovarian cancer and soft-tissue sarcoma, according to the authorised product information. Patients who have any questions about their treatment should speak to their doctor.
More information is available HERE
Update on nitrosamines in EU medicines
EU and national authorities are continuing their work to prevent and manage the presence of nitrosamine impurities in EU medicines. Nitrosamines are classified as probable human carcinogens (substances that could cause cancer) based on animal studies. They are present in some foods and water supplies and are not expected to cause harm when ingested at very low levels. In the few medicines where they have been found, the risk to patients is expected to be low. A review by EMA’s human medicines committee (CHMP) is currently considering evidence on how a nitrosamine called N-nitrosodimethylamine (NDMA) came to be present in some batches of ranitidine (a medicine for heartburn and stomach ulcer).
Also, EMA and national authorities are assessing the impact of recent tests which found NDMA in some EU batches of metformin medicines, used for diabetes. Further results from tests on metformin in the EU are being awaited. In line with previous advice, patients should continue taking their metformin medicines as usual. The risk from not having adequate diabetes treatment far outweighs possible risks from low levels of nitrosamines. An ongoing procedure aimed at providing guidance to companies on how to deal with nitrosamines in medicines is currently gathering evidence and considering opinions from leading experts in the EU. As a result of this procedure, which began in September 2019, measures to evaluate and mitigate the risk of nitrosamines are being implemented across the EU.
Authorities in the EU are also conducting an exercise to determine what lessons can be learnt from the presence of nitrosamines in sartans, which came to light in mid-2018. The lesson learnt group is currently finalising recommendations to prevent and better manage the presence of impurities in the future. EMA will continue working closely with national authorities, The European Directorate for the Quality of Medicines and HealthCare (EDQM) and international partners and will take all necessary measures to protect the quality of medicines in the EU.
More information is available HERE
The study evaluated the prevalence and nature of potentially inappropriate medications (PIMs) in a group of hospitalised older patients and verified whether the use of ‘Beers criteria’ and/or ‘START & STOPP’ criteria could lead to deprescribing of drugs and reduce the length of stay in the hospital. The use of criteria that detect inappropriate prescriptions reduced PIMs and adverse drug reactions, increased safety in older patients, and reduced the number of drugs prescribed but did not reduce the length of stay in hospital.
Read the article HERE
EAHP’s Statement Implementation Learning Collaborative programme (SILCC) is your opportunity to experience the daily work of a fellow hospital pharmacist in another European hospital pharmacy. The programme provides you with the unique opportunity to broaden your horizon by learning more about pharmacy procedures linked to the European Statements of Hospital Pharmacy. As SILCC Fellow you can choose between host institutions in Germany, Hungary, Italy, Spain, Sweden, Turkey and the United Kingdom. Have a look at the registration requirements and hand in your application today!
___________________________________________________________________________________________________________________
Consultations
Commission – Europe’s Beating Cancer Plan
The public consultation for Europe’s Beating Cancer Plan is seeking to collect feedback on the pillars of the plan which include cancer prevention, diagnosis, treatment, follow-up care and research from individual citizens, patients, and carers replying in their personal capacity as well as health professionals and organisations.
Deadline – 7th May 2020
Access consultation HERE
